We are delighted to announce the successful completion of the Epinephrine validation process, positioning us as one of the very few European manufacturers of this vital API. The scarcity of Epinephrine, exacerbated by supply chain disruptions, has adversely impacted patient access to essential first line treatments. Our commitment to reliability as an API supplier adds significant value to the global supply chain of this imperative pharmaceutical component.
Olon will manufacture the product following a proprietary process, that has been developed internally by its R&D department.
This strategic move aligns with Company’s mission to make a substantial contribution to the sustainability of the healthcare system, ensuring the launch of essential therapies in the generic market at an affordable price.
Epinephrine, also known as Adrenaline, is a hormone and medication utilized in treating various conditions, including allergic reactions, anaphylaxis, cardiac arrest, and superficial bleeding. Our dedication to addressing the shortage crisis underscores our broader commitment to global health and accessibility.